Regulatory & Legal

U.S. Gold's latest move at its CK Gold project is no mere update; it's a signal of intent to redefine the project's scale and chase historical riches.

After a 60-year battle against a defunct freeway, South Pasadena is selling eight historic homes, offering a rare chance at ownership in a tight market.

Leading Edge Materials confirms a low-cost, high-purity graphite process at its Swedish mine, positioning Woxna to supply Europe's booming EV battery market.

Biotech firm Sensorion drops one gene therapy to fast-track another, aiming to cure GJB2-related hearing loss, the leading cause of genetic deafness.

Facing burnout and fearing for patient safety, 250 clinicians at Seattle's top cancer centers are unionizing, challenging the very structure of modern healthcare.

A coal company and a First Nation are building a workforce before a mine even exists. Is this a new blueprint for resource projects or a gamble on approval?

As storms intensify, a new threat emerges: sophisticated fraud networks. Discover the hidden systems fueling post-disaster scams and the digital dragnet fighting back.

With strong shareholder backing from its AGM, First Mining Gold is poised to advance its Canadian projects. A closer look reveals a nuanced investor picture.

The firm's addition of tax expert Ed Hannon isn't just a personnel move; it's a strategic play to dominate the booming Delaware Statutory Trust market.

A new Glencore-funded study finds residents' arsenic levels are normal, blaming diet, not the Horne Smelter. But it clashes with past public health warnings, leaving a community to weigh conflicting science.

A survey reveals 75% of lab researchers prioritize peptide quality over price, a clear signal against the backdrop of a scientific reproducibility crisis.

Mosaic Clinical Technologies launches an AI-native platform that assists radiologists in real time, aiming to boost capacity and fight burnout in a strained field.

A market poised for 31% annual growth signals a new era for Alcohol-associated Liver Disease. As pharma chases a cure, a new class of drugs emerges.

As AI costs soar and security risks mount, a new open-source microhypervisor aims to rebuild trust from the silicon up. Is this the architectural shift we need?

A $3M drone contract is just the beginning. A construction firm's pivot to AI warfare reveals a deeper story about software-defined battlefields.

As AI-powered scams and account takeovers surge, institutions are ditching old tools for unified platforms that turn operational data into a strategic weapon.

Phase 2a data shows a new drug not only stops bone-destroying cancer but heals the damage, with no adverse events. This is a strategic game-changer.

New data reveals a grim reality: Texas rural roads are nearly three times deadlier than city streets, exposing a deep infrastructure and safety crisis.

An Alpharetta firm's milestone isn't just about shingles; it's a strategic play challenging the costly replacement model with sustainable, life-extending tech.

ResVita Bio's new board member signals a major shift. We explore how visionary leadership and living medicine are converging to tackle long-neglected diseases.